From silent fat accumulation to steatohepatitis, stellate cell activation, collagen deposition, and cirrhosis
Non-alcoholic fatty liver disease (NAFLD, now increasingly termed MASLD — metabolic dysfunction-associated steatotic liver disease) begins silently: triglyceride droplets accumulate inside hepatocytes once fat delivery and synthesis outpace oxidation and export. It is the most common chronic liver condition on Earth, tracking tightly with the global obesity and type 2 diabetes epidemic.
In insulin-resistant adipose tissue, hormone-sensitive lipase escapes normal suppression and continuously releases free fatty acids into the circulation. The liver, first in line via the portal vein, absorbs this flood of fatty acids and re-esterifies them into triglycerides for storage as cytoplasmic lipid droplets. At the same time, hyperinsulinemia paradoxically stimulates hepatic de novo lipogenesis through SREBP-1c, adding a second source of fat even as the liver becomes resistant to insulin's other metabolic effects.
Studies using stable-isotope tracing (Donnelly et al.) show that roughly 60% of hepatic triglyceride is imported from peripheral adipose lipolysis, about 25% is synthesized de novo in the liver itself, and only the remainder comes directly from dietary fat. This makes hepatic steatosis fundamentally a disease of whole-body energy surplus and adipose dysfunction, not simply "eating too much fat."
Early steatosis appears microscopically as small, multiple lipid droplets scattered through the hepatocyte cytoplasm. As triglyceride synthesis continues to outpace mitochondrial beta-oxidation and VLDL export, individual droplets coalesce into a single large macrovesicular globule that displaces the nucleus to the cell periphery — the classic histological hallmark of steatosis.
By imaging (MRI proton-density fat fraction, PDFF) or biopsy, a hepatic fat content above 5% of liver weight defines NAFLD. Below roughly 30–35% fat fraction, this process remains essentially benign and reversible: caloric restriction and 7–10% body-weight loss can normalize liver fat content within months in most patients.
For decades steatosis was framed by a "two-hit" hypothesis — fat accumulation as the first hit, a second insult (oxidative stress, inflammation) triggering NASH. Current understanding favors a "multiple-hit" model in which lipotoxic lipid species, gut-derived endotoxin, genetic variants (PNPLA3, TM6SF2), and adipose-derived inflammatory signals act in parallel rather than in strict sequence.
Only 20–30% of patients with simple steatosis progress to steatohepatitis; the rest remain in a comparatively stable, low-risk state for years. Identifying which patients are on the progressive trajectory — before fibrosis sets in — is the central clinical challenge addressed in later stages.
Not all stored fat is equally dangerous. As lipid handling capacity is exceeded, hepatocytes accumulate toxic lipid intermediates — free fatty acids, diacylglycerols, ceramides — that injure organelles directly. Resident liver macrophages (Kupffer cells) sense this stress and danger signals from the gut, releasing a cytokine storm that converts silent steatosis into active steatohepatitis (NASH).
Triglyceride itself is relatively inert, but the lipid species that accumulate alongside it are not. Saturated free fatty acids, lysophosphatidylcholine, diacylglycerols and ceramides directly damage the endoplasmic reticulum and mitochondria. Misfolded-protein accumulation triggers the unfolded protein response (UPR/ER stress), while excess fatty acid flux into mitochondria generates reactive oxygen species (ROS) faster than antioxidant defenses can neutralize them.
This lipotoxic injury activates c-Jun N-terminal kinase (JNK) signaling, promotes hepatocyte apoptosis via the mitochondrial pathway, and releases damage-associated molecular patterns (DAMPs) that alert the surrounding immune cells — the molecular bridge between a metabolic disorder and an inflammatory disease.
Kupffer cells, the liver's resident macrophages lining the sinusoids, are activated both by DAMPs from dying hepatocytes and by gut-derived lipopolysaccharide (LPS) reaching the liver through an increasingly permeable intestinal barrier — a phenomenon often called "leaky gut." Toll-like receptor 4 (TLR4) signaling on Kupffer cells triggers NF-κB activation and release of pro-inflammatory cytokines: TNF-α, IL-6 and IL-1β.
These cytokines amplify hepatocyte injury, recruit circulating monocytes and neutrophils into the liver, and — critically for the next stage — directly signal to hepatic stellate cells, priming them for activation.
Chronic lipid overload forces hepatocyte mitochondria into a state of persistent overwork. Electron transport chain efficiency declines, ROS leakage increases, and mitochondrial DNA itself becomes damaged, further impairing oxidative capacity in a self-reinforcing cycle. Malondialdehyde and 4-hydroxynonenal, byproducts of lipid peroxidation, roughly double in NASH liver tissue compared with simple steatosis.
This oxidative burden, combined with cytokine signaling, is what histologically separates NASH from steatosis: hepatocyte ballooning degeneration, Mallory-Denk bodies, and lobular inflammatory infiltrate — the NAFLD Activity Score criteria used to grade disease severity on biopsy.
Nestled in the perisinusoidal space of Disse, hepatic stellate cells normally sit quietly, storing most of the body's vitamin A as retinyl ester droplets. Under sustained cytokine and oxidative stress signaling from injured hepatocytes and activated Kupffer cells, these quiescent cells undergo one of the most consequential phenotypic switches in chronic liver disease.
In the healthy liver, hepatic stellate cells occupy the space of Disse between hepatocytes and sinusoidal endothelium, extending long cytoplasmic processes that wrap around the sinusoid. Their defining feature is a cytoplasm packed with lipid droplets storing retinyl esters — the liver holds roughly 80% of the body's total vitamin A reserve, and stellate cells are its principal warehouse. In this quiescent state they are non-proliferative, express low levels of extracellular matrix proteins, and play a supportive role in sinusoidal blood flow regulation.
Paracrine signals from injured hepatocytes and activated Kupffer cells convert stellate cells from a quiescent to an activated phenotype. Platelet-derived growth factor (PDGF) drives proliferation; transforming growth factor-beta (TGF-β1) is the dominant driver of matrix production; reactive oxygen species and apoptotic hepatocyte bodies provide additional activating signals. As activation proceeds, the cell loses more than 90% of its retinoid droplets, flattens, and begins expressing alpha-smooth muscle actin (α-SMA), the defining marker of the myofibroblast phenotype.
Once fully transdifferentiated, myofibroblasts are contractile, highly proliferative, and chemotactic, migrating toward sites of injury. They become the dominant collagen-producing cell of the fibrotic liver, secreting type I and type III collagen, and they also constrict sinusoids — contributing directly to the rise in intrahepatic vascular resistance that later manifests as portal hypertension. Because this activation step is central and largely reversible early on, stellate cells are the single most important pharmacological target for anti-fibrotic drug development.
Activated myofibroblasts steadily replace the liver's delicate basket-weave matrix with dense type I and III collagen. What begins as thin perisinusoidal streaks progresses, over years, into septa that bridge portal tracts to central veins — a process staged from F0 (none) to F4 (cirrhosis) and now trackable without biopsy using blood panels and elastography.
Myofibroblasts secrete type I and III collagen along with fibronectin and proteoglycans, while simultaneously downregulating matrix metalloproteinases (MMPs) and upregulating their tissue inhibitors (TIMPs). The result is a net accumulation of scar matrix that is not simply added on top of normal tissue but actively replaces the liver's specialized low-density basement membrane, capillarizing the sinusoids and impairing the exchange of nutrients and hormones between blood and hepatocytes.
Liver biopsy remains the reference standard but is invasive and subject to sampling error. FIB-4 (age, AST, ALT, platelet count) is a widely used blood-based score: values below 1.3 suggest low risk, 1.3–2.67 indeterminate, and above 2.67 a high likelihood of advanced fibrosis. Transient elastography (FibroScan) and MR elastography measure liver stiffness directly in kilopascals, correlating strongly with histological fibrosis stage and now guiding referral, monitoring, and clinical trial enrollment.
Management intensifies with each fibrosis stage. Foundational therapy at every stage remains structured weight loss — 7–10% body weight reduction meaningfully improves fibrosis, and bariatric surgery achieves histological resolution in the majority of eligible patients. GLP-1 receptor agonists (semaglutide) have shown NASH resolution and fibrosis improvement in phase 3 trials. In March 2024 resmetirom (a liver-selective thyroid hormone receptor-beta agonist) became the first FDA-approved drug specifically for NASH with moderate-to-advanced fibrosis (F2–F3), reducing fibrosis and NASH activity in roughly one in four treated patients at one year.
| Product | Indication | Trial Design | Key Result |
|---|---|---|---|
At F4, the liver's normal lobular architecture is replaced by regenerative parenchymal nodules encased in dense fibrous septa. Blood flow through the organ becomes tortuous and high-resistance, driving portal hypertension, while the risk of decompensation and hepatocellular carcinoma (HCC) rises steadily — NASH cirrhosis is now among the leading indications for liver transplantation worldwide.
As fibrous septa fully encircle islands of surviving hepatocytes, these islands proliferate into regenerative nodules that lack normal portal-central vascular relationships. Blood entering the liver can no longer percolate efficiently through the sinusoidal network and instead shunts around nodules through newly formed vascular channels, reducing effective hepatocyte perfusion and function even in nodules that appear histologically intact.
Elevated intrahepatic resistance from fibrotic septa, capillarized sinusoids, and stellate-cell-mediated sinusoidal constriction raises the hepatic venous pressure gradient (HVPG). Above 10 mmHg, portal hypertension becomes clinically significant, promoting splanchnic vasodilation, formation of esophageal and gastric varices, ascites, and splenomegaly. Above roughly 12 mmHg, the risk of variceal hemorrhage rises sharply, making HVPG one of the strongest prognostic measurements in cirrhosis.
Compensated cirrhosis can remain clinically silent for years, but roughly one in five patients decompensates — developing ascites, variceal bleeding, or hepatic encephalopathy — within a decade. Because chronic inflammation and regenerative nodule turnover promote malignant transformation, biannual ultrasound (with or without alpha-fetoprotein) surveillance for hepatocellular carcinoma is recommended for all NASH cirrhosis patients. NASH is now one of the fastest-growing indications for liver transplantation, reflecting both the scale of the underlying obesity epidemic and the limited number of patients caught early enough for anti-fibrotic therapy to reverse the process.